Structure and function of the transketolase from Mycobacterium tuberculosis and comparison with the human enzyme by Fullam, Elizabeth et al.
rsob.royalsocietypublishing.org
Research
Cite this article: Fullam E, Pojer F, Bergfors T,
Jones TA, Cole ST. 2011 Structure and function
of the transketolase from Mycobacterium
tuberculosis and comparison with the
human enzyme. Open Biol 2: 110026.
http://dx.doi.org/10.1098/rsob.110026
Received: 15 November 2011
Accepted: 16 December 2011
Subject Area:
biochemistry/microbiology/structural biology/
molecular biology
Keywords:
transketolase, Mycobacterium tuberculosis,
X-ray crystallography, pentose pathway,
enzyme kinetics
Author for correspondence:
Stewart T. Cole
e-mail: stewart.cole@epfl.ch
†Present address: School of Biosciences,
University of Birmingham, Edgbaston,
Birmingham, B15 2TT, UK.
Electronic supplementary material is available
at http://dx.doi.org/10.1098/rsob.110026
Structure and function
of the transketolase from
Mycobacterium tuberculosis
and comparison with the
human enzyme
Elizabeth Fullam1,†, Florence Pojer1, Terese Bergfors2,
T. Alwyn Jones2 and Stewart T. Cole1
1Global Health Institute, EPFL, 1015 Lausanne, Switzerland
2Department of Cell and Molecular Biology, Uppsala University, 751 24 Uppsala, Sweden
1. Summary
The transketolase (TKT) enzyme in Mycobacterium tuberculosis represents a
novel drug target for tuberculosis treatment and has low homology with the
orthologous human enzyme. Here, we report on the structural and kinetic
characterization of the transketolase from M. tuberculosis (TBTKT), a homodi-
mer whose monomers each comprise 700 amino acids. We show that TBTKT
catalyses the oxidation of donor sugars xylulose-5-phosphate and fructose-6-
phosphate as well as the reduction of the acceptor sugar ribose-5-phosphate.
An invariant residue of the TKT consensus sequence required for thiamine
cofactor binding is mutated in TBTKT; yet its catalytic activities are unaffected,
and the 2.5A ˚ resolution structure of full-length TBTKT provides an explanation
for this. Key structural differences between the human and mycobacterial TKT
enzymes that impact both substrate and cofactor recognition and binding were
uncovered. These changes explain the kinetic differences between TBTKT and
its human counterpart, and their differential inhibition by small molecules.
The availability of a detailed structural model of TBTKT will enable differences
between human and M. tuberculosis TKT structures to be exploited to design
selective inhibitors with potential antitubercular activity.
2. Introduction
Mycobacterium tuberculosis is the aetiologic agent of tuberculosis (TB), a disease
that is one of the leading causes of death from a single infectious agent world-
wide. The World Health Organization currently estimates that 1.8 billion
people, approximately one-third of the world’s population, are infected with
M. tuberculosis, and that there are 9 million new active cases annually and
2 million deaths each year as a result of infection [1]. TB treatment is compli-
cated, requiring at least three drugs, of long duration and often accompanied
by side-effects. This has resulted in poor compliance to treatment regimens
that, in turn, have contributed to the emergence of numerous multi-drug-
resistant (MDR) and extensively drug-resistant (XDR) strains that further com-
plicate the therapy. In the case of XDR TB, there are usually no effective
therapeutic agents remaining to constitute a successful combination therapy
regimen [2]. In conjunction with HIV, this represents a serious problem.
& 2012 The Authors. Published by the Royal Society under the terms of the Creative Commons Attribution
License http://creativecommons.org/licenses/by/3.0/, which permits unrestricted use, provided the original
author and source are credited.Therefore, there is an urgent need for the identification of
novel targets and pathways within M. tuberculosis in order
to develop new chemotherapeutic agents.
Analysis of the genome sequence of M. tuberculosis H37Rv
[3], together with saturation transposon mutagenesis by
Himar1 [4], has led to the identification of a number of differ-
ent proteins and biosynthetic pathways, which may be
attractive targets for antitubercular therapy as they are pre-
dicted to be essential for the survival of M. tuberculosis in
vitro. One such pathway that has been identified as essential
for the survival of M. tuberculosis in vitro is the pentose-
phosphate pathway (PPP). Furthermore, evidence that this
pathway is an important metabolic process for mycobacteria
is provided by its conservation in Mycobacterium leprae, as
this obligate pathogen has undergone massive gene decay,
resulting in acore set of genes that are required for its survival
in humans [5]. A putative functional transketolase (TKT) gene
product, which is part of this non-oxidative branch of the PPP,
has been identified in M. tuberculosisthrough a numberof pro-
teomic studies and two-dimensional liquid chromatography–
mass spectrometry studies [6–10].
TKT enzymes (EC2.2.1.1) have been identified and
studied in several organisms, including humans [11,12],
Saccharomyces cerevisiae [13–15], Escherichia coli [16], maize
[17], spinach [18] and Plasmodium falciparum [19], the causa-
tive agent of malaria. These are typically cytosolic enzymes
have a molecular mass of 70–75 kDa, with the homo-
dimer being the active entity. This class of enzyme uses the
cofactor thiamine pyrophosphate (TPP) and a divalent
metal cation to catalyse the cleavage of carbon–carbon
bonds to transfer two ketol carbon units from donor ketose
sugars, such as xylulose-5-phosphate, to acceptor aldose
sugars, such as ribose-5-phosphate or erythrose-4-phosphate,
resulting in the production of sedoheptulose-7-phosphate
or fructose-6-phosphate, respectively (figure 1) [20–23].
The reaction proceeds via a Ping Pong Bi Bi mechanism.
A broad range of donor and acceptor substrates have been
reported, with the bacterial, plant and yeast enzymes
having a wider range of substrate recognition than human
TKT enzymes [22].
The first TKT structure that was reported in literature was
from S. cerevisiae (pdb 1trk) [24]. Subsequently, a number of
other structures have been solved, both with and without
sugar substrates and cofactor, for other species including
E. coli (pdb 2r5n) [25], maize (pdb 1itz) [17], Leishmania mex-
icana (pdb 1r9j) [26], Thermus thermopilus (pdb 2e6k), Bacillus
anthracis (pdb 3hyl) and Francisella tularensis (pdb 3kom).
Until recently, no mammalian TKT structures were available;
however, the human structure has recently been solved (pdb
3ooy and 3mos) [11]. All of the TKT structures from the
different species show a similar overall TKT fold and arrange-
ment of three domains [13,17,24,26,27]. Domains I (1–322)
and II (323–527), numbering from the TKT enzyme from
S. cerevisiae, have been shown to be involved in dimeric inter-
actions of each monomeric subunit and are also involved in
TPP cofactor binding and recognition. The third domain,
which comprises the last approximately 150 amino acids, is
believed to be involved in the regulation of the activity of
the enzyme and in stereochemical control of the sugar sub-
strates, in which D-threo at the C-3 and C-4 positions are
favoured [13,24,28–30]. Studies have shown that the TKT
enzyme from E. coli is still active in the absence of the third
domain [28].
Despite its importance in plants and bacteria, detailed
studies of TKTs from a mycobacterial species have not yet
been reported. The cell wall of M. tuberculosis is unique in its
complexity, comprising threecovalentlyattached layers (pepti-
doglycan, arabinogalactan and mycolic acids), and is very
important to the survival of M. tuberculosis, its pathogenicity
and impermeability to drugs. One of the first committed steps
in the production of the arabinogalactan layerof M. tuberculosis
is the production of D-ribose-5-phosphate. The biosynthesis of
D-ribose-5-phosphate can potentially occur through two pro-
cesses [31]: either the enzyme ribose-5-phosphate isomerase
(Rv2465) can convert ribulose-5-phosphate to D-ribose-5-
phosphate [32], or the TKT enzyme (Rv1449) can convert
sedoheptulose-7-phosphate to D-ribose-5-phosphate. Given
that the ribose-5-phosphate isomerase enzyme Rv2465 is not
essential based on the studies of Sassetti et al.[ 4 ] ,i ti st h o u g h t
that the TKT plays a key role in linking the non-oxidative part
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Figure 1. Transketolase enzyme catalysed reactions. TKT catalyses the cleavage of carbon–carbon bonds to transfer two ketol carbon units from donor ketose
sugars, like xylulose-5-phosphate, to acceptor aldose sugars, such as ribose-5-phosphate or erythrose-4-phosphate, resulting in the production of sedoheptulose-7-
phosphate or fructose-6-phosphate.
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2ofthePPPtobiosynthesisofpentosesugarsandhencetoessen-
tial arabinans in cell wall biosynthesis. A number of current
antitubercular drugs target key components of the cell wall,
including isoniazid and ethionamide (which block mycolic
acid synthesis [33–35]), ethambutol (which targets arabinoga-
lactan formation [36]) and cycloserine (which inhibits the
biosynthesis of peptidoglycan [37,38]). Recently, a new class
of compounds, 1,3-benzothiazin-4-ones, have been identified
thatpreventtheformationofarabinosebyinhibitionofthedec-
aprenyl-phosphoribose epimerase activity catalysed by the
DprE1 and DrpE2 proteins [39].
Given the potential importance of TKT in the production of
arabinaninM.tuberculosis,thisbiosyntheticpathwayisanattrac-
tivetargetforidentifyingadditional,novelantitubercularagents.
As the first step in this process, we report here our structural
and functional studies of the TKT enzyme from M. tuberculosis
(TBTKT), encoded by gene rv1449c, and discuss structural
differences between the human, yeast andbacterial homologues.
3. Material and methods
AllchemicalsandreagentswerepurchasedfromSigma-Aldrich,
unless otherwise stated. Restriction enzymes were obtained
from New England Biolabs. Double-distilled water was used
throughout.
3.1. Plasmid construction
The putative TKT gene, rv1449c, was amplified in two steps
by PCR from cosmid I392 of M. tuberculosis using gene-
specific primers, followed by gateway adaptor primers with
attB1 and attB2 sites for incorporation into the gateway
entry vector pDONR207 (Invitrogen). The gateway adaptor
forward primer encoded a thrombin recognition sequence
ctggttccgcgtggatc. The first PCR step used primers
50CTGGTTCCGCGTGGATCCACCACACTCGAAGAGATCT
CCG (forward) and 50-CAAGAAAGCTGGGTCTCAGTTA
TCCAGCGCTCGTTCG-30 (reverse). The second PCR reaction
used primers 50-ggggACAAGTTTGTACAAAAAAGCAGGC
TTCctggttccgcgtggatc-30 (forward) and 50-ggggACCACTTT
GTACAAGAAAGCTGGGTC-30 (reverse). For both PCR reac-
tions, PCR amplification consisted of 30 cycles (958C, 2 min;
958C, 1 min; 608C, 30 s; 728C, 3 min), followed by an exten-
sion cycle (10 min at 728C). The resulting PCR product was
cloned into the pDONR207 vector and the resultant plasmid
was used to transfer the gene sequence into pET160_DEST
(Invitrogen; N-term hexa-histidine-tag) by homologous recom-
bination. The Rv1449c_pET160_DEST plasmid obtained was
sequenced fully and used for protein expression.
3.2. Heterologous overexpression of transketolase
enzyme from Mycobacterium tuberculosis
Escherichia coli BL21(DE3) transformed with the Rv1449c_
pET160_DEST plasmid was grown at 278C to an optical
density at 600 nm (OD600) of 0.6–0.8 in 2xLuria-Bertani
(LB) medium supplemented with 100 mgm l
21 ampicillin.
The production of the protein was induced with 500 mM iso-
propyl-b-thiogalactopyranoside (IPTG) and the cultures were
grown at 168C overnight with shaking. The cells were har-
vested by centrifugation at 6000 g for 20 min at 48C, and
the cell pellet was resuspended in lysis buffer (50 mM
sodium phosphate, 500 mM sodium chloride, 2 mM TPP, 10
per cent glycerol, 5 mM b-mercaptoethanol, 0.1% Triton-X
100 and pH 7.4) and Complete Protease Inhibitor Cocktail
(Roche). The cells were freeze–thawed and sonicated.
Following centrifugation at 18000 g for 30 min at 48C, the
supernatant was loaded onto a Cobalt-Talon affinity column.
3.3. Purification of transketolase enzyme from
Mycobacterium tuberculosis
Recombinant TBTKT was purified in three steps. The soluble
lysate was incubated with Talon-resin (Clontech) at 48Cf o r
1 h. The column was washed with 20 mM sodium phosphate,
100 mM sodium chloride, 2 mM TPP, 10 per cent glycerol,
5m Mb-mercaptoethanol (pH 7.4) and the His-tagged protein
eluted with increasing concentrations of imidazole. The 50
and 250 mM imidazole fractions as determined by SDS-PAGE
were pooled, concentrated (Amicon centrifugal device) and
run on a Resource Q column (GE Healthcare) in 20 mM
sodium phosphate, 100 mM sodium chloride, 2 mM TPP and
5m Mb-mercaptoethanol (pH 7.4), and eluted with sodium
chloride (0.1–1 M). Fractions containing TBTKT were pooled
and purified further using size exclusion chromatography.
Gel filtration experiments were carried out on a Superdex 200
16/60 column (GE Healthcare). The gel filtration column was
run in 20 mM sodium phosphate, 100 mM sodium chloride,
2m MT P P ,5m Mb-mercaptoethanol (pH 7.4). Fractions con-
taining TBTKT were pooled, and the dimer and monomeric
fractions collected separately.
3.4. Crystallization of transketolase enzyme from
Mycobacterium tuberculosis
Monomeric TBTKT was concentrated to 8mg ml
21 (Amicon
ultracentrifugal concentrators from Millipore) and buffer
exchanged into 20 mM Tris-HCl, 1 mM ethylenediaminete-
traacetic acid (EDTA), 1 mM dithiothreitol (DTT) (TED)
buffer plus 5 mM MgCl2, 5 mM TPP (pH 7.6) or 20 mM
glycyl-glycine (Gly-Gly), 5 mM MgCl2, 10 mM TPP
(pH 7.7). The crystals were grown using the sitting-drop
vapour-diffusion technique by mixing equal volumes
(150 nl) of concentrated TBTKT with mother liquor using a
protein crystallization robot (Mosquito, TTP LabTech).
TBTKT crystals grew within one week at 228C, in 0.1 M
ammonium acetate, 0.1 M bis-tris pH 5.5 and 17%w/v poly-
ethylene glycol 10000 with the protein in buffer 20 mM
Gly-Gly, 5 mM MgCl2, 10 mM TPP (pH 7.7).
3.5. Data collection, structure determination
and refinement
The TBTKT crystal was cryoprotected with 30% v/v glycerol
and flash frozen in liquid nitrogen prior to data collection.
Data were collected on beamline PXIII at the Swiss Light
Source (Villigen, Switzerland) with a mar225 mosaic CCD
detector. The space group was determined, and the data
were integrated, scaled and merged using the program XDS
[40]. PHASER [41] was used to solve the TBTKT structure
by molecular replacement with a TBTKT model, built using
SWISS-MODEL [42] and the TKT structure from E. coli (PDB
code 2r8o chain A [25]) as a template. The structure was
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3refined by iterative cycles of alternating manual rebuilding in
O [43] and COOT [44], and reciprocal space crystallographic
refinement with REFMAC5 [45]. The successful refinement was
dependent on making use of the non-crystallographical sym-
metry for averaging using the tools within O. Data processing
and refinement statistics are shown in table 1. Preparation
of structure-related images was carried out with PYMOL (ver-
sion 0.99, Schro ¨dinger, LLC). Sequences were aligned with
CLUSTALW2, and sequence figures were generated with ESPRIPT
version 2.2 [47,48].
The atomic coordinates and experimental structure factor
data of the refined M. tuberculosis TKT have been deposited in
the protein data bank (PDB code 3RIM).
3.6. Steady-state kinetic analysis
Activity of the recombinant TKT was measured by the
reduction of potassium ferricyanide by the a-carbanion inter-
mediate formed, as described previously by Kochetov [49].
The reaction was carried out in 100 ml in a 96-well plate, in
50 mM Gly-Gly buffer (pH 7.6), 2 mM magnesium chloride,
0.1 mM TPP, 0.5 mM potassium ferricyanide, 3 mM fruc-
tose-6-phosphate (6FP) and recombinant TBTKT enzyme,
and the reduction of potassium ferricyanide was monitored
at 420 nm on a Tecan Infinite M200 plate reader at 378C.
The Km,app values were determined by varying the con-
centration of substrate from 0 to 4 mM. Alternatively, the
activity of the recombinant TKT was measured using
the auxiliary enzymes: triosephosphate isomerase and
a-glycerophosphate dehydrogenase. The reaction (100 ml)
was performed in a 96-well plate, in 50 mM Gly-Gly buf-
fer (pH 7.6), 2 mM magnesium chloride, 0.1 mM TPP,
0.4 mM NADH 4 mM ribose-5-phosphate (R5P) and 4 mM
xylulose-5-phosphate (X5P), 8 units of triosephosphate iso-
merase and 8 units of a-glycerophosphate dehydrogenase.
Oxidation of NADH was followed spectrophotometrically
by measuring the absorbance at 340 nm (A340), as descri-
bed previously by Kochetov [21]. Substrate concentrations
were varied to below and above the Km,app value. The pro-
gram PRISM (version 5, GraphPad Software, La Jolla, CA,
www.graphpad.com) was used for nonlinear regression
analysis of kinetic data. Inhibitors oxythiamine (Sigma)
and 5-benzyl-3-phenylpyrazolo[1,5-a]pyrimidin-7(4H)-one
(Chembridge Screening Library) were added at a final
concentration of 30 mM and tested in both enzyme assays.
3.7. Testing for in vitro growth inhibition
of Mycobacterium tuberculosis
The inhibitory activity of oxythiamine was tested at a concen-
tration range of 0–100 mgm l
21 in the resazurin reduction
assay as described previously [39].
4. Results
4.1. Identification and production of transketolase
enzyme from Mycobacterium tuberculosis
A putative TKT gene (tkt, rv1449c; hereafter TBTKT)
was annotated in the genome of M. tuberculosis (http://tuber
culist.epfl.ch/index.html) based on the presence of a consen-
sus sequence for TPP binding and extensive sequence
similarity to other known TKT genes. The predicted open
reading frame of TBTKT contains a specific sequence motif
of THDSIGLGEDGPTHQPIE that has been identified pre-
viously in other TKT proteins [50] and corresponds to
amino acids 490–507 in this enzyme. Interestingly, a second
sequence motif, which is common to thiamine cofactor-
binding enzymes, is a GDG consensus motif followed by 21
amino acids varying in sequence identity. In M. tuberculosis,
the GDG motif has been replaced by SDG (amino acids
176–178), and this is also the case in all other sequenced
mycobacterial TKTs (figure 2; electronic supplemen-
tary material, S1). No other known TKT enzymes that have
been studied contain this mutation in the TKT consensus
sequence [11].
To produce recombinant TBTKT protein, primers were
designed and the full-length tkt gene was cloned with an
N-terminal hexa-histidine tag and over-expressed in an
E. coli expression system. Soluble, active protein was obtained
Table 1. Data collection and reﬁnement statistics. Numbers in brackets
denote values for the highest-resolution shell.
TBTKT (3RIM)
data collection statistics
beam line PXIII – Swiss Light
Source
space group P1
resolution range (A ˚) 50–2.49 (2.64–2.49)
wavelength 0.979000
cell dimensions
cell axial lengths (A ˚) a ¼ 75.5, b ¼ 80.1,
c ¼ 130.0
cell angles (
o) a ¼ 82.2, b ¼ 81.2,
g ¼ 66.4
number of molecules in the
asymmetric unit
4
redundancy 3.9 (3.65)
completeness (%) 96.6 (91.2)
Rmeas
a 15.9 (54.0)
mean I/sI 7.90 (2.77)
reﬁnement statistics
resolution range 50–2.49
Rwork/ Rfree 0.22/0.27
number of atoms
protein/ligand/water 21206/156/410
Ramachandran
favoured/allowed/disallowed (%) 88.4/11.6/0
average B-factor (A ˚2)
protein/ligand/solvent 27.2/27.6/19.3
root mean square deviations
bond lengths (A ˚) 0.017
bond angles (A ˚) 1.634
aRmeas is defined by Diederichs & Karplus [46].
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4in a yield of 10 mg l
21 bacterial culture and purified to
apparent homogeneity.
4.2. Overall structure of transketolase enzyme from
Mycobacterium tuberculosis
Crystal trials of TBTKT were set down as described (§3.4).
Crystals typically grew after 7 days, and diffraction data
were collected from crystals that were formed in 17% w/v
polyethylene glycol 10 K, 0.1 M ammonium acetate, in
0.1 M bis-tris at pH 5.5. Crystals of the TBTKT were in sym-
metry group P1 with four molecules predicted in the
asymmetric unit, with a Matthew’s coefficient [51] of
2.3 A ˚ 3 Da
–1 and a solvent content of 46 per cent. The struc-
ture was solved by using molecular replacement with a
homology model of TBTKT built using SWISS-MODEL [42]
and the E. coli TKT structure (pdb 2r8o) [25] that has
42 per cent amino acid sequence identity to TBTKT. In
almost all protein molecules, electron density could be
observed for residues 6–700, the last residue of the full-
length protein. The final model was refined with tight
Figure 2. Sequence comparison of transketolase enzyme from Mycobacterium tuberculosis (TBTKT) and human transketolase (TKT). Sequence alignment of TBTKT
versus human TKT using the programs CLUSTALW2 and ESPRIPT version 2.2 [47,48]. Numbering corresponds to the sequence of TBTKT. Identical residues are indicated
by a red background, and conserved residues are indicated by red characters. The secondary structure elements of TBTKT are shown above the sequences, and those
of human TKT are shown below.
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5non-crystallographic restraints to a resolution of 2.5 A ˚ and
consists of 2776 amino acids, 410 water molecules, four TPP
molecules, 4 Mg
2þ ions and eight glycerol molecules, with
an Rwork of 22 per cent and an Rfree of 27 per cent (pdb
3RIM; table 1).
The TBTKT enzyme forms a homodimer, where the two
monomeric units are related by a non-crystallographic two-
fold axis. There are two dimers per asymmetric unit that
are related to each other by a twofold axis to create a non-
crystallographic screw axis parallel to the crystallographic
Z-axis. The overall structure of each TBTKT monomer con-
sists of three domains interconnected by flexible linker
regions (figure 3a,b). The N-terminal pyrophosphate (PP)-
binding domain (domain I) that binds the PP part of TPP
(residues 6–299) consists of a central five-stranded parallel
b-sheet, surrounded by 11 a-helices. The pyridine (Pyr)-
binding domain (domain II) that involves the aminopyrimi-
dine moiety of TPP (residues 377–550) comprises a central
six-stranded parallel b-sheet with seven a-helices surround-
ing it. The C-terminal domain (Domain III, residues
571–700) forms a central five-stranded mixed b-sheet with
four parallel strands and one antiparallel strand. These
three domains are linked by linkers (linker 1: residues
300–376; linker 2: residues 551–570; figure 3a,b). Domains I
and II are mostly involved in dimer formation, while the
third domain makes rather few contacts to the other subunit
(figure 3a,b). The Protein Interfaces, Surfaces and Assemblies
(PISA) service at the European Bioinformatics Institute
(http://www.ebi.ac.uk/msd-srv/prot_int/pistart.html) gives
a complexation significance score of 0.614 between chains A
and B (or chains C and D), indicating that the interface
plays an essential role in dimer complexation with a large
number of residues involved. There are 60 hydrogen bonds
and 15 salt-bridges between the two monomers. In total, a
surface of around 4200 A ˚ 2 is buried upon formation of the
dimer (chains A and B and chains C and D), with 17 per
cent of the total residues being involved in its formation.
The solvent accessible surface area of a monomeric subunit
is 25785 A ˚ 2. TBTKT is also found as a homodimer in solution
as seen by size exclusion chromatography (data not shown)
and therefore it is likely that the homodimer found in the
crystal structure is the biologically relevant unit as shown
for other TKT enzymes. Two important conserved residues
involved in dimeric interaction are Glu182 and Glu441, the
buried acidic side chains of which form a hydrogen bond
interaction, allowing Glu441 to interact with the N10 atom
of the aminopyrimidine ring of the TPP [13].
The subunits of different TKT structures were compared
and superimposed using DALILITE version 3 [52]. The
TBTKT and human TKT structures can be superimposed
with a root mean square deviation (RMSD) value of 2.3 A ˚
and a high Dali Z-score of 36.7 (584 Ca atoms were aligned,
23% sequence identity to TBTKT). With other TKTs, the fol-
lowing values were obtained: for yeast (pdb 1trk), RMSD
of 1.4 A ˚ , Z-score of 48.4 (678 Ca atoms, 44% sequence iden-
tity); for E. coli (pdb 2r5n), RMSD of 1.6 A ˚ , Z-score of 48.0
domain I
domain II
domain III
linker 1
domain I
domain II
domain III
linker 1
90°
linker 2
linker 2
(a)( b)
(d) (c)
Figure 3. Crystal structure of TBTKT and superposition to human tkt. (a) Surface representation of TBTKT dimer with bound cofactor TPP (pink) with one monomer
in grey and the second monomer coloured by domains (blue, domain I; orange, domain II; green, domain III; red, linkers 1, 2). (b) Dimer representation of TBTKT
with one monomer represented as surface and coloured by B-factor, and the second one as a cartoon with the domains coloured as in (a). (c) Superposition of
TBTKT and human tkt (pdb code 3MOS) monomers depicted as cartoon representation. The domains are colour-coded as in (a) and (b), with human tkt in lighter
colours compared with TBTKT. (d) The structures are rotated 908 around the twofold axis compared with (c).
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6(663 Ca atoms, 42% sequence identity); for B. anthracis (pdb
3hyl), RMSD of 1.3 A ˚ , Z-score of 50.1 (663 Ca atoms, 47%
sequence identity); for maize (pdb 1itz), RMSD of 1.5 A ˚ ,Z -
score of 49.4 (666 Ca atoms, 44% sequence identity). The
combined superimposition results of TBTKT and other TKT
structures confirm the similarity of the overall fold and
domain topology of TKT enzymes from different species.
However, the TBTKT enzyme is 87 amino acids longer than
the human TKT. The deletions in the human TKT correspond
to two loop regions at amino acids 153–167 (in domain I) and
amino acids 413–432 (in domain II) in TBTKT. No binding is
predicted to occur between these residues and substrate or
TPP cofactor. In addition, linker 1 is longer and more struc-
tured, forming a helix-turn-helix in TBTKT compared with
human TKT—77 amino acids (residues 300 to 376) versus
39 amino acids (residues 277 to 315)—and may result in
some specificity (figure 3c,d).
4.3. Binding of TPP and Mg
2þ ion to transketolase
enzyme from Mycobacterium tuberculosis
and comparison with homologues from
different species
Well-defined electron density has revealed the binding
pocket of the cofactor TPP and an Mg
2þ ion in the TBTKT
structure. Each TBTKT monomer contains one TPP molecule
and one Mg
2þ ion, suggesting that each active site is equival-
ent, and this has been found to be the case for other reported
structures of TKT enzymes [11,13,15,17,25]. An active site
cleft is formed between the two monomeric units allowing
the cofactors TPP and Mg
2þ to bind, such that the N-terminal
domain I of chain A binds the PP moiety of TPP, and
domain II of chain B interacts with the aminopyrimidine
ring. The PP moiety of TPP is anchored in place through a
number of hydrogen bonds formed with residues Thr48,
His85, Ser176, Asp177, Gly178, Asn207, Ile209 and His283
from one monomer (figure 4a). The Mg
2þ ion is octahedrally
coordinated to residues Asp177, Asn207 and Ile209, along
with two oxygen atoms of the PP moiety of the cofactor
TPP and a water molecule.
Of the eight residues of TBTKT that are involved in
hydrogen bonding to the PP moiety of TPP, four residues
are conserved among all TKT enzymes, including the mam-
malian versions, and these correspond to His85, Asp177,
Asn207 and His283 in TBTKT. One non-conserved amino
acid residue is Thr48, and this is specific to mycobacterial
TKTs (electronic supplementary material, figure S1). By
superposing the available structures, Thr48 corresponds to
an alanine residue in both yeast (pdb 1ngs) [15] and E. coli
(1qgd) [25], and a leucine in maize (pdb 1itz) [17]; this resi-
due is unable to interact with the cofactor. However, the
equivalent serine residue in human TKT (Ser40) also has
the potential to hydrogen bond with the terminal PP
moiety in a manner similar to that of Thr48 as found in the
TBTKT structure. Ile209 is highly conserved among non-
mammalian species and is replaced by a leucine residue in
human TKT (Leu187), but this does not affect its interaction
to the divalent ion through its backbone carbonyl group.
The other non-conserved residue that is involved in the bind-
ing of the PP segment of TPP is the hydroxyl side chain of
Ser176 (figure 4b). This is noteworthy since Ser176 represents
the mutation in the consensus sequence GDG to SDG. This
non-conserved residue in the motif does not affect the overall
fold of the protein and forms a turn separating a b-stand from
an a-helix in the bab-fold. In TBTKT, the hydroxyl side chain
is positioned to hydrogen bond with the PP group of the
cofactor. However, in the yeast and human structures,
the equivalent glycine residues (Gly156 in yeast TKT and
Gly154 in human TKT) lack this hydroxyl side chain and
cannot form such a hydrogen bond with the PP moiety. The
backbone carbonyl oxygen of the glycine residue is pointed
away from the cofactor and does not compensate for this lack
of hydrogen bond in this way. We demonstrated in our kinetic
experiments that mutating GDG to SDG does not affect
the activity of the enzyme, and this can be explained at the
structural level by the remaining hydrogen bonding of
the backbonenitrogenof anotherresidue, Gly178,correspond-
ing to Glu157 in human and Gly158 in yeast, to the PP of TPP.
Moreover, additional interactions are formed in human TKT
between Lys75 and Lys244 and the PP moiety of TPP that
are not present in TBTKT (replaced by Ala83 and Ile269,
respectively; figure 4b).
Asn207
Mg
Ile209
Asp177
Gly178
Ile211
Thr48
His85
His283 Ser176
Val439
Leu402
Glu441
Tyr470
Phe467
Phe464
Gly133
Leu135
Lys75
Lys244
Ala83
Ile269
Mg
Ser176
Gly154
TPP
His503
(a) (b)
Figure 4. Structure of the cofactor-binding site in TBTKT. (a) Illustration showing TPP cofactor as cyan sticks, Mg
2þ as a cyan sphere as well as selected amino acid
residues in stick representation. Amino acids contributed by different monomers are indicated by different colour-coding. (b) Superposition of the TBTKT (green) to
human TKT (silver) with cofactors TPP and Mg
2þ, and selected residues in stick representation.
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7The pyrimidine ring portion of TPP binds in a hydropho-
bic core that is formed by residues from both monomers:
Leu135 and Ile211 from one monomer, and Leu402, Val439,
Phe464, Phe467 and Tyr470 from the second monomer
(figure 4a). The pyrimidine ring forms p-stacking interactions
with the phenyl ring of residue 467. There are also hydrogen
bond interactions between the pyrimidine ring, and Glu441,
Gly133 and His503. Glu441 has been demonstrated to be
important in activating the cofactor by protonating the N10
position of the aminopyrimidine ring [13], and it appears
that this will also occur in TBTKT. Of these residues,
Glu441 and Gly133, as well as Phe464, Phe467 and Leu135,
are conserved among yeast and human TKT enzymes.
Leu402 and Tyr470 are replaced by slightly more hydrophilic
residues in the human equivalent (Thr342 and Arg395,
respectively). However, these residues are positioned in a
similar way as the yeast TKT and TBTKT residues, and do
not form extra hydrogen bonds to the aminopyrimidine
ring of TPP.
4.4. Kinetic studies of transketolase enzyme from
Mycobacterium tuberculosis
Apparent kinetic (Km,app) constants were determined for
TBTKT with the two donor substrates—xylulose-5-phosphate
(X5P) and fructose-6-phosphate (F6P)—and the acceptor sub-
strate ribose-5-phosphate (R5P). R5P had a Km,app of 0.82+
0.12 mM, F6P had a Km,app of 0.63+0.09 mM and X5P had
a Km,app of 0.35+0.12 mM (table 2). These kinetic constant
values for the TBTKT enzyme are comparable with kinetic
constants previously determined for TKTs from S. cerevisiae
[15,21], spinach [53], E. coli [16] and P. falciparum [19]
(table 2), with X5P having the highest binding affinity. As
explained by the crystal structure, mutation of GDG to
SDG has no effect upon the TKT reaction as the cofactor
TPP still binds to the active pocket in the same manner via
additional hydrogen bounds formed (e.g. by Lys75, Lys244
and Gly157 in human TKT). Based on these kinetic studies,
it appears that the TBTKT is more similar to the TKTs
from bacteria, yeast and plants because it was shown that
fructose-6-phosphate is a poor substrate for the human
TKT enzyme, with a Km,app of 7 mM [22], whereas in
TBTKT, F6P is a good substrate for catalysis, with a Km,app
of 0.63 mM (table 2).
Previous extensive mechanistic studies of TKT enzymes
have shown that this class of enzyme follows Ping Pong
Bi Bi reaction kinetics where the donor and acceptor sub-
strates are not able to bind to the protein simultaneously
[14,22,25,54,55].
The structure suggests that this would also be the case for
TBTKT because the substrate cleft is not large enough to
allow binding of donor and acceptor sugar substrates simul-
taneously. The yeast TKT enzyme has been co-crystallized
with the substrate erythrose-4-phosphate (pdb 1ngs) [56],
with no large conformational changes observed upon bind-
ing of the substrate, and this led to the identification of a
number of catalytically important residues for substrate rec-
ognition. These residues are all conserved and correspond
to His45, His283, Arg378, Ser405, His491, Asp499 and
Arg552 in TBTKT (figure 5a). The residues Arg378, Arg552
and His491 have been shown to be important in the recog-
nition of the phosphate moiety of the sugar [56]. These
residues in TBTKT can be superimposed upon those from
the yeast structure and human structure (figure 5a), and it
is envisaged that the TKT sugar substrates for the TBTKT
enzyme are able to bind in a similar manner, and the
enzyme reacts via a Ping Pong Bi Bi reaction mechanism
[29,30,57,58].
Two inhibitors of the human TKT were tested for inhibi-
tory activity against purified TBTKT enzyme, as well as on
live M. tuberculosis cells. Oxythiamine is an analogue of the
cofactor TPP and inhibits TKT activity in human tumour
cells in vivo [59], although it is only a weak inhibitor in vitro
[60]. Oxythiamine has also been found to inhibit weakly
the TKT enzyme from P. falciparum but to have in vivo activity
against P. falciparum [19]. The other inhibitor of human
TKT—5-benzyl-3-phenylpyrazolo[1,5-a]pyrimidin-7(4H)-one
(5BPPO), a compound identified from a high-throughput
screen of 64000 compounds against human TKT—was also
found to be active against three cancer cell lines, and had
IC50 values in the low micromolar range [60]. Oxythiamine
had no inhibitory activity on the TBTKT enzyme at a rela-
tively high concentration of 30 mM (table 3). Instead,
oxythiamine, at this concentration, increased the rate of the
reaction of the TBTKT enzyme by 30 per cent under the
assay conditions tested. We are unable to explain this result
structurally because oxythiamine is predicted to bind in the
same position as TPP in both the TBTKT and human TKT
enzymes (results not shown). In addition, 5BPPO also had
Table 2. Steady-state kinetic constants, Km,app (mM), of TBTKT and other transketolase enzymes. Assay conditions for TBTKT are detailed under ‘§2’. n.d., not
determined.
R5P F6P X5P reference
M. tuberculosis 0.8+0.1 0.6+0.1 0.4+0.1 this study
human 0.61+0.36 7 mM 0.30+0.79 [11], [22]
S. cerevisiae 0.4 1.8 0.21 [21]
S. cerevisiae 0.15+0.21 n.d. 0.70+0.10 [15]
S. cerevisiae H481A 0.15+0.50 n.d. 1.24+0. 90 [15]
S. cerevisiae H481Q n.d. n.d. 4.08+0.51 [15]
spinach chloropasts 0.33 n.d. 0.06 [53]
E. coli 1.4 1.1 0.16 [16]
P. falciparum n.d. 2.25+0.5 n.d. [19]
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8no inhibitory effect on the activity of TBTKT at a con-
centration of 30 mM (table 3), which is higher than the
IC50 value of 4 mM determined for the human TKT enzyme
[60]. When tested for their inhibitory effects on the growth
of M. tuberculosis in vitro, both compounds (oxythiamine
and 5BPPO) displayed no growth inhibition at concentrations
as high as 100 mgm l
21, corresponding to a molar concen-
tration of 332 mM for oxythiamine and 227 mM for 5BPPO
(table 3).
5. Discussion
Here, we have successfully cloned, expressed and character-
ized, both kinetically and structurally, TBTKT, the first
TKT enzyme to be characterized from mycobacteria. Kineti-
cally, TBTKT has very similar kinetic constants to the TKT
enzymes from yeast, E. coli, maize and spinach, despite the
GDG to SDG mutation in the TKT consensus sequence. The
TBTKT also displays broad substrate specificity for a range
of phosphorylated sugars and in this respect differs from
the mammalian TKT, as the human TKT enzyme has a
much higher Km,app and lower affinity for fructose-6-
phosphate, compared with other identified substrates [11].
Phylogenetic studies have shown that mammalian TKT
enzymes have diverged distinctly from equivalent TKTs in
plants, yeast and bacteria, and therefore may have diversified
to play a different, more selective role in humans.
Structurally, TBTKT consists of three domains with the
same overall fold and domain topology as those of other
TKTs whose structures have been determined [11,13,24,25,
56,61,62]. Dimer formation and binding of the TPP cofactor
occur via domains I and II, with domain III being more
likely to play a regulatory role in substrate recognition as
shown for the E. coli counterpart [28]. The recently reported
structure of the human TKT structure [11] has allowed us
to determine key structural differences between the human
TKT enzyme and the TBTKT. Although the fold of the
His45/37/30 His45/37/30 His45/37/30
His283/258/263 His283/258/263 His283/258/263
Arg378/318/359 Arg378/318/359 Arg378/318/359
Ser405/345/386 Ser405/345/386 Ser405/345/386
His491/416/469 His491/416/469 His491/416/469 Asp499/424/477 Asp499/424/477 Asp499/424/477
Arg552/474/528 Arg552/474/528 Arg552/474/528
E4P E4P E4P
TPP TPP TPP
Mg
His491/416 His491/416 His491/416
His45/37 His45/37 His45/37
His283/258 His283/258 His283/258
His503/Gln428 His503/Gln428 His503/Gln428
Gly404/Asn344 Gly404/Asn344 Gly404/Asn344
Gln189/Ile211 Gln189/Ile211 Gln189/Ile211
Ala285/Lys260 Ala285/Lys260 Ala285/Lys260
His285/77 His285/77 His285/77
(a) (a) (b) (b)
Figure 5. Superposition of active sites of TBTKT (pdb code 3RIM), human TKT (pdb code 3MOS) and yeast TKT (pdb code 1ngs). (a) Illustration of the three
structures with sphere representation of substrate erythrose-4-phosphate (E4P) and cofactors TPP and Mg
2þ as found in the active site of yeast TKT. Amino acid
residues (amino acid numbering: TBTKT/human TKT/yeast TKT) involved in the binding of E4P to yeast TKT (light blue orange) as well as the corresponding TBTKT
(green and pink) and human TKT (dark blue/yellow) amino acid residues are shown in stick representation. (b) Illustration of TBTKT and human TKT with selected
amino acid residues of TBTKT (magenta) and human TKT (yellow). Cofactors TPP and Mg
2þ are represented as spheres. Same orientation as in (a).
Table 3. Effects of human TKT inhibitors on TBTKT and in vitro growth of M. tuberculosis. Assay conditions are detailed under §2. 5BPPO, 5-benzyl-3-
phenylpyrazolo[1,5-a]pyrimidin-7(4H)-one.
inhibitor structure IC50 TBTKT
(mM)
speciﬁc activity TBTKT
a
(%)
MIC (mgm l
21)/
(mM)
Oxythiamine .30 130 .100/.332
5BPPO .30 100 .100/.227
aSpecific activity of the TBTKT enzyme calculated compared with a 5% DMSO control taken as 100% activity.
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9human TKT structure is similar overall to that of the TBTKT
structure, despite only 27 per cent amino acid sequence
similarity, we have identified important differences between
the two structures, which may be exploited with a view to
identifying specific inhibitors of TBTKT. It is important
to ensure that inhibitors of the TKT enzyme in M. tuberculosis
show specificity and do not inhibit human TKT or other
thiamine-dependent enzymes such as pyruvate dehydrogen-
ase, in order to minimize potential side-effects associated
with a decrease in thiamine availability [22]. First, the sub-
strate-binding channel in the human TKT enzyme is
narrower than the TBTKT equivalent. This structural differ-
ence is believed to result in a more selective substrate
specificity of human TKT compared with TBTKT [11].
The entrance of this substrate channel in the human TKT
enzyme contains a lysine residue (Lys260) that is predicted
to be involved in the binding of the phosphate of the sugar
substrate [11]. This lysine residue is replaced by smaller
residues in TBTKT and yeast TKT (Ala285 and Ala265,
respectively), leaving more space to accommodate larger
substrates (figure 5b).
TPP cofactor binding differs slightly between TBTKT and
human TKT. The hydrophobic core that binds the pyrimidine
ring of TPP in TBTKT is more hydrophilic in the human TKT
enzyme. Moreover, the human enzyme displays a quasi-
irreversible binding of TPP, which has not been observed
for the yeast and E. coli homologues, in which the activity
of recombinant human TKT in not dependent upon an
excess of TPP or a divalent cation in the assay mixture. This
is believed to be conferred in part by residue Gln189
(replaced by Ile211 in TBTKT) by sterically hindering
cofactor dissociation [11] (figure 5b).
Another important difference between human and myco-
bacterial TKTs is the absence of the characteristic TKT
five-histidine cluster from human TKT, as one of these
histidines (His481 in yeast and His503 in TBTKT) has been
replaced by a glutamine (Gln428; figure 5b). In yeast,
His481 has mutated to Gln481, resulting in an increase in
Km,app values for X5P from 70 mM in wild-type yeast TKT
to 4080 mM in the His481Gln yeast TKT mutant, suggesting
a role for this residue in catalysis and substrate recognition
in the activation of TPP through proton abstraction of the
40-imino group of the cofactor [15].
Overall, the human TKTenzyme is 87 amino acids shorter
than the TBTKT enzyme. The deletions in the human TKT
correspond to two loops, between amino acids 153–167
and amino acids 413–432 in TBTKT. No possible interactions
are predicted to occur between these loops and substrate or
TPP. Also, the linker region between domains I and II
(residues 300–376) is longer in TBTKT and forms a helix-
turn-helix motif that may confer some specificity. On the
basis of these structurally identified differences, it should
be possible to design specific inhibitors rationally. Indeed, it
is encouraging that oxythiamine and 5BPPO both inhibit
human TKT [60], yet showed no inhibition of TBTKT activity
or the growth in vitro of M. tuberculosis.
TBTKT represents a potential novel target for anti-
tubercular therapy because it is predicted to be essential for
in vitro growth of M. tuberculosis [4]. Additionally, TBTKT is
believed to have an important role in production of precur-
sors for the biosynthesis of the arabinans essential for the
cell wall [31]. The tkt gene has been shown to be twofold
upregulated 6 days after bacterial infection of host macro-
phages, and this probably reflects a response to the stress
and toxic oxygen metabolites within this environment [10].
Additionally, this pathway is also responsible for the pro-
duction of erythrose-6-phosphate that feeds into the
shikamate pathway, producing folate, a de novo process in
prokaryotic species. Escherichia coli mutants that lack TKT
activity are auxotrophic for shikimic acid [63], while yeast
mutants that are TKT-deficient are auxotrophic for aromatic
amino acids [64]. TKT inhibitors are being considered for
development for cancer therapy because TKT activity is upre-
gulated in proliferative cells, and specificity for TKT enzymes
in cancer cells can therefore be achieved through targeting an
upregulated metabolic process [60].
In summary, TBTKT is the first TKT to have been
characterized both structurally and biochemically from a
mycobacterial species. The structure has revealed that,
although the overall fold, domain organization and active-
site architecture are very similar to those of other known
TKTs, there are key structural and kinetic differences between
the human TKT and TBTKT enzymes. This will enable us to
exploit the TBTKT structure for rational drug design in an
effort to find novel agents for antitubercular therapy.
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